{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:42:06Z","timestamp":1790635326306,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\\CSA\\017\\2017"],"award-info":[{"award-number":["NMRC\\CSA\\017\\2017"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40271-022-00586-8","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T01:02:27Z","timestamp":1655168547000},"page":"679-690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Patient Medication Preferences for Managing Dry Eye Disease: The Importance of Medication Side Effects"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7556-1601","authenticated-orcid":false,"given":"Semra","family":"Ozdemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon Wan Jie","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Jia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adithya","family":"Bhaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"issue":"3","key":"586_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276\u201383.","journal-title":"Ocul Surf"},{"issue":"3","key":"586_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334\u201365.","journal-title":"Ocul Surf"},{"issue":"1","key":"586_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/cxo.12210","volume":"98","author":"LL Tan","year":"2015","unstructured":"Tan LL, et al. Prevalence of and risk factors for symptomatic dry eye disease in Singapore. Clin Exp Optom. 2015;98(1):45\u201353.","journal-title":"Clin Exp Optom"},{"issue":"4","key":"586_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ajo.2013.12.023","volume":"157","author":"A Paulsen","year":"2014","unstructured":"Paulsen A, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014;157(4):799\u2013806.","journal-title":"Am J Ophthalmol"},{"key":"586_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","volume":"182","author":"KF Farrand","year":"2017","unstructured":"Farrand KF, et al. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"586_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1542-0124(12)70040-X","volume":"4","author":"KK Nichols","year":"2006","unstructured":"Nichols KK. Patient-reported symptoms in dry dye disease. Ocul Surf. 2006;4(3):137\u201345.","journal-title":"Ocul Surf"},{"issue":"1","key":"586_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/02713683.2010.519850","volume":"36","author":"M Li","year":"2011","unstructured":"Li M, et al. Anxiety and depression in patients with dry eye syndrome. Curr Eye Res. 2011;36(1):1\u20137.","journal-title":"Curr Eye Res"},{"issue":"3","key":"586_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","volume":"143","author":"B Miljanovi\u0107","year":"2007","unstructured":"Miljanovi\u0107 B, et al. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409\u201315.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"586_CR9","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/eye.2010.67","volume":"24","author":"L Tong","year":"2010","unstructured":"Tong L, et al. Impact of symptomatic dry eye on vision-related daily activities: the Singapore Malay Eye Study. Eye. 2010;24(9):1486\u201391.","journal-title":"Eye"},{"key":"586_CR10","doi-asserted-by":"crossref","unstructured":"Lemp MA. Epidemiology and classification of dry eye. In: Sullivan DA, Dartt DA, Meneray MA, editors. Lacrimal gland, tear film, and dry eye syndromes 2. Berlin: Springer; 1998. p. 791\u2013803.","DOI":"10.1007\/978-1-4615-5359-5_111"},{"issue":"1","key":"586_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamaophthalmol.2015.4331","volume":"134","author":"S Holfinger","year":"2016","unstructured":"Holfinger S, et al. Effect of regulatory requirement for patient-specific prescriptions for off-label medications on the use of intravitreal bevacizumab. JAMA Ophthalmol. 2016;134(1):45\u20138.","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"586_CR12","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","volume":"112","author":"LD Barber","year":"2005","unstructured":"Barber LD, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112(10):1790\u20134.","journal-title":"Ophthalmology"},{"issue":"3","key":"586_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/09273948.2019.1587470","volume":"28","author":"M-J Kang","year":"2019","unstructured":"Kang M-J, et al. Evaluation of the efficacy and safety of a novel 0.05% cyclosporin A topical nanoemulsion in primary Sj\u00f6gren\u2019s syndrome dry eye. Ocular Immunol Inflamm. 2019;28(3):370\u20138.","journal-title":"Ocular Immunol Inflamm"},{"issue":"3","key":"586_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/00003088-200544030-00003","volume":"44","author":"DD-S Tang-Liu","year":"2005","unstructured":"Tang-Liu DD-S, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet. 2005;44(3):247\u201361.","journal-title":"Clin Pharmacokinet"},{"key":"586_CR15","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.2147\/PPA.S180280","volume":"12","author":"G Reach","year":"2018","unstructured":"Reach G, et al. Disruption in time projection and non-adherence to long-term therapies. Patient Prefer Adherence. 2018;12:2363.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"586_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","volume":"30","author":"J Yu","year":"2011","unstructured":"Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30(4):379\u201387.","journal-title":"Cornea"},{"key":"586_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/1758-5899.12247","volume":"8","author":"J Lim","year":"2017","unstructured":"Lim J. Sustainable health care financing: the Singapore experience. Glob Pol. 2017;8:103\u20139.","journal-title":"Glob Pol"},{"issue":"9","key":"586_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2893.2010.01343.x","volume":"18","author":"A Hauber","year":"2011","unstructured":"Hauber A, et al. Patient preferences and assessment of likely adherence to hepatitis C virus treatment. J Viral Hepat. 2011;18(9):619\u201327.","journal-title":"J Viral Hepat"},{"issue":"4","key":"586_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1464-5491.2009.02696.x","volume":"26","author":"A Hauber","year":"2009","unstructured":"Hauber A, et al. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416\u201324.","journal-title":"Diabet Med"},{"key":"586_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2147\/PPA.S20445","volume":"5","author":"A Hauber","year":"2011","unstructured":"Hauber A, et al. Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). Patient Prefer Adherence. 2011;5:307\u201314.","journal-title":"Patient Prefer Adherence"},{"key":"586_CR21","doi-asserted-by":"crossref","unstructured":"Johnson F et al. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med Care 2007;45(6):545\u2013552","DOI":"10.1097\/MLR.0b013e318040ad90"},{"issue":"3","key":"586_CR22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1053\/j.gastro.2007.04.075","volume":"133","author":"F Johnson","year":"2007","unstructured":"Johnson F, et al. Crohn\u2019s disease patients\u2019 risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133(3):769\u201379.","journal-title":"Gastroenterology"},{"issue":"9","key":"586_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/hec.870","volume":"13","author":"E Lancsar","year":"2004","unstructured":"Lancsar E, Savage E. Deriving welfare measures from discrete choice experiments: inconsistency between current methods and random utility and welfare theory. Health Econ. 2004;13(9):901\u20137.","journal-title":"Health Econ"},{"issue":"7\u20138","key":"586_CR24","first-page":"431","volume":"33","author":"D Caldeira","year":"2014","unstructured":"Caldeira D, Vaz-Carneiro A, Costa J. The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis. Revista Portuguesa de Cardiologia (English Edition). 2014;33(7\u20138):431\u20137.","journal-title":"Revista Portuguesa de Cardiologia (English Edition)"},{"issue":"5","key":"586_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1007\/s11096-019-00895-3","volume":"41","author":"AS Jarab","year":"2019","unstructured":"Jarab AS, Mukattash TL. Exploring variables associated with medication non-adherence in patients with COPD. Int J Clin Pharm. 2019;41(5):1202\u20139.","journal-title":"Int J Clin Pharm"},{"key":"586_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.seizure.2016.12.006","volume":"45","author":"G O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke G, O\u2019Brien JJ. Identifying the barriers to antiepileptic drug adherence among adults with epilepsy. Seizure. 2017;45:160\u20138.","journal-title":"Seizure"},{"issue":"4","key":"586_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090635","volume":"9","author":"JA Whitty","year":"2014","unstructured":"Whitty JA, et al. A think aloud study comparing the validity and acceptability of discrete choice and best worst scaling methods. PLoS\u00a0One. 2014;9(4): e90635.","journal-title":"PLoS\u00a0One"},{"key":"586_CR28","doi-asserted-by":"crossref","unstructured":"Johnson F et al. Experimental design for stated-choice studies. In: Kanninen B, editor. Valuing environmental amenities using stated choice studies. Springer; 2006. p. 159\u2013202","DOI":"10.1007\/1-4020-5313-4_7"},{"issue":"1","key":"586_CR29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/hec.1452","volume":"19","author":"S \u00d6zdemir","year":"2010","unstructured":"\u00d6zdemir S, et al. Who pays attention in stated-choice surveys? Health Econ. 2010;19(1):111\u20138.","journal-title":"Health Econ"},{"issue":"7","key":"586_CR30","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jval.2020.01.023","volume":"23","author":"S Ozdemir","year":"2020","unstructured":"Ozdemir S, et al. Patient preferences for medications in managing type 2 diabetes mellitus: a discrete choice experiment. Value Health. 2020;23(7):842\u201350.","journal-title":"Value Health"},{"key":"586_CR31","volume-title":"Getting the most from CBC. Sawtooth Software Research Paper Series","author":"R Johnson","year":"2003","unstructured":"Johnson R, Orme B. Getting the most from CBC. Sawtooth Software Research Paper Series. Sequim: Sawtooth Software; 2003."},{"key":"586_CR32","volume-title":"Sample size issues for conjoint analysis studies","author":"B Orme","year":"1998","unstructured":"Orme B. Sample size issues for conjoint analysis studies. Sequim: Sawtooth Software Technical Paper; 1998."},{"issue":"8","key":"586_CR33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0191-2615(02)00046-2","volume":"37","author":"WH Greene","year":"2003","unstructured":"Greene WH, Hensher DA. A latent class model for discrete choice analysis: contrasts with mixed logit. Transp Re Part B Methodol. 2003;37(8):681\u201398.","journal-title":"Transp Re Part B Methodol"},{"issue":"3","key":"586_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40271-019-00360-3","volume":"12","author":"JM Gonzalez","year":"2019","unstructured":"Gonzalez JM. A guide to measuring and interpreting attribute importance. Patient Patient Centered Outcomes Res. 2019;12(3):287\u201395.","journal-title":"Patient Patient Centered Outcomes Res"},{"issue":"10","key":"586_CR35","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00417-008-0875-7","volume":"246","author":"HJ Beckers","year":"2008","unstructured":"Beckers HJ, et al. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol. 2008;246(10):1485\u201390.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"586_CR36","first-page":"785","volume":"9","author":"HG Lemij","year":"2015","unstructured":"Lemij HG, et al. Patient satisfaction with glaucoma therapy: reality or myth? Clin Ophthalmol (Auckland, NZ). 2015;9:785\u201393.","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"8","key":"586_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/01.ico.0000134183.47687.75","volume":"23","author":"P Reddy","year":"2004","unstructured":"Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea. 2004;23(8):751\u201361.","journal-title":"Cornea"},{"issue":"6","key":"586_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037711","volume":"7","author":"S Waduthantri","year":"2012","unstructured":"Waduthantri S, et al. Cost of dry eye treatment in an Asian clinic setting. PLoS\u00a0One. 2012;7(6): e37711.","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"586_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000360","volume":"4","author":"E Messmer","year":"2019","unstructured":"Messmer E, et al. Comparing the needs and preferences of patients with moderate and severe dry eye symptoms across four countries. BMJ Open Ophthalmol. 2019;4(1): e000360.","journal-title":"BMJ Open Ophthalmol"},{"key":"586_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2147\/OPTH.S233194","volume":"14","author":"D White","year":"2020","unstructured":"White D, et al. Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease. Clin Ophthalmol (Auckland, NZ). 2020;14:875\u201383.","journal-title":"Clin Ophthalmol (Auckland, NZ)"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-022-00586-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-022-00586-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-022-00586-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:09:22Z","timestamp":1744715362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-022-00586-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s40271-022-00586-8","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"assertion":[{"value":"8 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by a Grant awarded by National Medical Research Council of Singapore (NMRC\\CSA\\017\\2017) to Dr. Louis Tong (PI). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the SingHealth Centralised Institutional Review Board (CIRB Ref. No.: 2018\/2022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants prior to commencing interviews.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provide this consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Data are available upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Semra Ozdemir, Sharon Wan Jie Yeo, Jia Jia Lee, Eric Finkelstein, and Louis Tong contributed to the study conception and design. Semra Ozdemir and Jia Jia Lee developed the study materials. Sharon Wan Jie Yeo performed the interviews. Semra Ozdemir and Adithya Bhaskar conducted the analysis. All authors contributed to the interpretation of the results, writing, and critical review of the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}